TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad; and pharmaceuticals, including iron supplement, therapeutic agent for urinary system, expectorant/mucolytic agent, anticancer drug, antihypertensive drug, and antidiabetic. It also provides medical detection platform for breast cancer recurrent risk detection and postoperative detection platform for liver cancer, as well as philips non-invasive positive pressure ventilation and accessories. TCM Biotech International Corp. was founded in 1998 and is headquartered in New Taipei City, Taiwan.
Metrics to compare | 4169 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4169PeersSector | |
---|---|---|---|---|
P/E Ratio | 187.4x | −21.5x | −0.6x | |
PEG Ratio | 5.86 | 0.02 | 0.00 | |
Price/Book | 4.8x | 3.5x | 2.6x | |
Price / LTM Sales | 7.5x | 34.9x | 3.3x | |
Upside (Analyst Target) | 31.9% | 0.0% | 39.5% | |
Fair Value Upside | Unlock | −28.7% | 4.9% | Unlock |